Doctor Safia Chatur
Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)
Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: a participant level pooled analysis of CREDENCE and CANVAS
Event: ESC Congress 2024
Topic: Pharmacotherapy
Session: Modern views on worsening heart failure
Safety and efficacy of sacubitril/valsartan in patients with heart failure with mildly reduced or preserved EF after a worsening heart failure event based on diuretic use in PARAGLIDE-HF
Event: Heart Failure 2024
Topic: Pharmacotherapy
Session: Chronic heart failure - treatment 11
Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial
Event: ESC Congress 2023
Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)
Session: Insights from recent HFpEF trials 1
Dapagliflozin reduces loop diuretic requirement over time in patients with heart failure with mildly reduced or preserved ejection fraction in the DELIVER Trial
Event: Heart Failure 2023
Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)
Session: Pharmacotherapy
Renal and hemodynamic effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction in DELIVER
Event: Heart Failure 2023
Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)
Session: Chronic heart failure - pathophysiology 1
Effects of dapagliflozin on hospitalizations for heart failure according to severity of inpatient treatment course: the DELIVER Trial
Event: Heart Failure 2023
Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)
Session: Heart failure with preserved ejection fraction (HFpEF) 1
